NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical
company pioneering and delivering therapies that transform the lives of
patients with rare diseases, today announced that the Japanese Ministry
of Health, Labor and Welfare (MHLW) has granted teduglutide orphan drug
designation for the treatment of Short Bowel Syndrome (SBS). Also, due
to the strong medical need for SBS treatments in Japan, the MHLW’s
expert committee on Unapproved New Drugs and New Indications with High
Medical Needs requested that NPS Pharma Japan K.K. develop teduglutide
for adult SBS earlier this year.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.